SLC10A3 Antibody

What is SLC10A3 and why is it important in research?

SLC10A3 (solute carrier family 10 member 3) is a protein that belongs to the SLC10 family, which encodes transporters for various agents including bile acids and steroidal hormones. The protein consists of 477 amino acids with a calculated molecular weight of approximately 50 kDa. SLC10A3 has gained research importance due to its emerging role in various biological processes, including potential implications in cancer biology, particularly in low-grade gliomas where its expression correlates with clinical outcomes and immune cell infiltration .

What applications are validated for SLC10A3 antibodies?

SLC10A3 antibodies have been validated for multiple research applications including Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)/Immunocytochemistry (ICC), and ELISA. Specific antibodies like 19909-1-AP have demonstrated positive Western blot detection in 37°C incubated A549 cells, positive IHC in human pancreas tissue, and positive IF/ICC in HeLa cells . Other antibodies such as CAC14762 have been similarly validated for ELISA, WB, and IHC applications .

What cell lines and tissues show reliable SLC10A3 expression for antibody validation?

Based on validation data, researchers can reliably detect SLC10A3 in:

• Cell lines: A549 cells (for WB) and HeLa cells (for IF/ICC)

• Tissues: Human pancreas tissue has shown positive IHC detection

• Pathological samples: Low-grade glioma tissues have demonstrated higher SLC10A3 expression compared to normal brain tissue

What are the recommended dilutions for different applications of SLC10A3 antibodies?

Note: These dilutions are based on antibody 19909-1-AP, and it is recommended that researchers titrate antibodies in each testing system to obtain optimal results as they may be sample-dependent .

How should sample preparation be optimized for SLC10A3 antibody detection in different applications?

For IHC applications, antigen retrieval methods significantly impact SLC10A3 detection efficiency. The recommended protocol suggests using TE buffer pH 9.0 for antigen retrieval; alternatively, citrate buffer pH 6.0 may be used . For Western blot applications, incubating A549 cells at 37°C has shown positive results, suggesting temperature conditions may affect SLC10A3 protein conformation or expression levels . When designing experiments, researchers should consider these sample preparation variables to optimize antibody performance.

How do I distinguish between the different molecular weight forms of SLC10A3 in Western blot analysis?

SLC10A3 antibodies typically detect the protein at both 50 kDa and 48 kDa, representing different forms of the protein. The calculated molecular weight of SLC10A3 is 50 kDa (477 amino acids), which corresponds to the full-length protein . The 48 kDa band may represent post-translationally modified forms or alternatively spliced variants. To distinguish between these forms, researchers should use positive controls with known SLC10A3 expression patterns and consider performing additional experiments such as immunoprecipitation or mass spectrometry to confirm the identity of detected bands.

What controls should be included when using SLC10A3 antibodies in experiments?

For rigorous scientific validation, the following controls should be included:

• Positive tissue/cell controls: A549 cells for WB, human pancreas tissue for IHC, and HeLa cells for IF/ICC

• Negative controls: Samples known not to express SLC10A3 or IgG isotype controls

• Loading controls: For WB, use housekeeping proteins like GAPDH or β-actin

• Knockdown/knockout validation: When possible, include SLC10A3 knockdown or knockout samples to confirm antibody specificity

How can I combine SLC10A3 antibody with immune markers for multiplex immunohistochemistry studies?

For multiplex immunohistochemistry (mIHC) studies involving SLC10A3, researchers have successfully combined SLC10A3 antibody detection with various immune markers. In studies of low-grade gliomas, SLC10A3 protein expression has been correlated with macrophage markers, CD4+ T cell markers, and B cell markers using mIHC techniques . When designing multiplex panels:

• Select antibodies raised in different host species to avoid cross-reactivity

• Optimize individual antibody concentrations before multiplexing

• Determine the appropriate sequential staining order

• Consider using tyramide signal amplification for enhanced sensitivity

• Include appropriate controls to assess bleed-through between fluorescence channels

Spearman correlation analysis can then be used to quantify the relationship between SLC10A3 expression and immune cell markers at the translational level .

What are the challenges in interpreting SLC10A3 expression data in different pathological conditions?

Interpreting SLC10A3 expression data presents several challenges that researchers should consider:

• Tumor heterogeneity: In low-grade gliomas, SLC10A3 expression correlates with tumor grade, histological type, IDH wild type, and non-codel 1p19q status , indicating complex interactions with other molecular markers.

• Immune microenvironment influence: SLC10A3 expression shows strong relationships with immune checkpoints such as PD-1 (r=0.568), PD-L1 (r=0.478), PD-L2 (r=0.549), HAVCR2 (r=0.585), IDO1 (r=0.433), and LAG3 (r=0.348) . These correlations suggest that immune factors may influence SLC10A3 expression or vice versa.

• Discrepancies between mRNA and protein levels: Researchers should note that mRNA upregulation doesn't always translate to increased protein expression. Therefore, validation at both transcriptional and translational levels is recommended.

• Subcellular localization variations: Different pathological conditions may affect the subcellular localization of SLC10A3, potentially impacting antibody detection efficiency.

How can SLC10A3 antibodies be used to investigate its potential role as a prognostic biomarker in cancer?

Based on recent research findings, SLC10A3 shows promise as a prognostic biomarker, particularly in low-grade gliomas. To investigate this potential:

What technical considerations are important when using SLC10A3 antibodies in studying tumor immune microenvironment?

When investigating the tumor immune microenvironment with SLC10A3 antibodies, researchers should consider:

• Sample preparation: Fresh frozen versus formalin-fixed paraffin-embedded (FFPE) tissues may yield different staining patterns and intensities. For FFPE samples, optimized antigen retrieval methods are crucial.

• Spatial analysis: Consider employing digital pathology and spatial analysis tools to quantify the co-localization of SLC10A3 with immune cell markers within different tumor compartments (tumor core, invasive margin, stroma).

• Batch effects: Staining variations between batches may confound results. Implement standardized protocols and include technical replicates.

• Quantification methods: Define clear scoring criteria for SLC10A3 positivity (e.g., H-score, percentage positive cells, or average cell intensity). Studies have analyzed parameters such as number of SLC10A3 positive cells and SLC10A3 average cell intensity in total area, tumor area, and stroma area .

• Integration with flow cytometry: Consider combining IHC findings with flow cytometry analysis for more comprehensive immune phenotyping.

What is the recommended protocol for Western blot using SLC10A3 antibody?

Western Blot Protocol for SLC10A3 Detection:

• Sample preparation:

  • Lyse cells in RIPA buffer with protease inhibitors

  • For optimal results with certain cell lines (e.g., A549), consider incubating cells at 37°C before lysis

• Protein separation:

  • Load 20-30 μg of protein per lane

  • Use 10% SDS-PAGE gels for optimal separation of the 48-50 kDa SLC10A3 protein

• Transfer and blocking:

  • Transfer to PVDF membrane (recommended over nitrocellulose for SLC10A3)

  • Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Primary antibody incubation:

  • Dilute SLC10A3 antibody 1:500-1:1000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

• Secondary antibody and detection:

  • Wash membrane 3x with TBST (5 minutes each)

  • Incubate with HRP-conjugated secondary antibody (anti-rabbit) at 1:5000 for 1 hour

  • Wash 3x with TBST

  • Develop using enhanced chemiluminescence (ECL) substrate

• Expected results:

  • Primary bands at approximately 50 kDa and 48 kDa

  • Validate with positive control samples (e.g., A549 cells)

What are the key considerations for optimizing immunohistochemistry with SLC10A3 antibody?

Optimizing IHC for SLC10A3:

• Tissue preparation:

  • Use freshly cut sections (4-6 μm thickness) from FFPE tissues

  • For certain tissues, freshly frozen sections may provide better antigen preservation

• Antigen retrieval:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

  • Heat-induced epitope retrieval using pressure cooker or microwave methods

• Antibody dilution optimization:

  • Start with the recommended range (1:20-1:200)

  • Perform a dilution series to determine optimal concentration for your specific tissue

  • Include positive control tissue (e.g., human pancreas)

• Detection system selection:

  • DAB-based chromogenic detection for standard IHC

  • Fluorescence-based detection for co-localization studies

  • Consider signal amplification methods for low-abundance targets

• Counterstaining and mounting:

  • Hematoxylin counterstaining (for chromogenic IHC)

  • DAPI nuclear counterstain (for fluorescence IHC)

  • Use appropriate mounting media to prevent signal fading

• Controls:

  • Positive tissue control (human pancreas)

  • Negative control (primary antibody omitted or isotype control)

  • Blocking peptide control if available

How can I overcome common challenges when using SLC10A3 antibodies in multiplex immunofluorescence studies?

Troubleshooting Multiplex Immunofluorescence with SLC10A3:

• Signal cross-talk:

  • Ensure appropriate fluorophore selection with minimal spectral overlap

  • Implement spectral unmixing algorithms during image analysis

  • Use sequential antibody application and imaging when necessary

• Antibody cross-reactivity:

  • Select primary antibodies from different host species

  • When using multiple rabbit antibodies, consider tyramide signal amplification with sequential antibody stripping

• Signal-to-noise ratio optimization:

  • Increase blocking time (2-3 hours with 5-10% normal serum from the species of secondary antibody)

  • Optimize antibody concentrations individually before multiplexing

  • Consider longer but more dilute primary antibody incubations (e.g., 1:400 overnight vs. 1:200 for 1 hour)

• Tissue autofluorescence:

  • Pretreat tissues with autofluorescence reducing agents (e.g., sodium borohydride)

  • Use confocal microscopy with spectral detection capabilities

  • Implement computational autofluorescence subtraction during image analysis

• Signal quantification:

  • Establish clear thresholds for positive staining

  • Use digital image analysis software for unbiased quantification

  • Analyze parameters including number of positive cells, average cell intensity, and spatial distribution

• Validation of multiplexed findings:

  • Confirm key findings with single-plex staining of consecutive sections

  • Correlate with other methods (e.g., flow cytometry, RNA-seq)

How should I analyze and interpret correlation data between SLC10A3 expression and immune markers?

Analysis of SLC10A3-Immune Marker Correlations:

• Quantitative metrics:

  • Cell density (cells/mm²) for each marker

  • Percentage of positive cells in defined regions (tumor, stroma, margin)

  • Mean fluorescence intensity as a proxy for expression level

  • Co-localization coefficients for multiple markers

• Statistical approaches:

  • Spearman correlation is recommended for analyzing relationships between SLC10A3 and immune markers

  • Consider reporting both correlation coefficient (r) and significance value (p)

  • For SLC10A3 and immune checkpoints, strong correlations have been observed: PD-1 (r=0.568, P=2.29e-45), PD-L1 (r=0.478, P=8.98e-31), PD-L2 (r=0.549, P=6.74e-42), HAVCR2 (r=0.585, P=9.63e-49), IDO1(r=0.433, P=5.16e-25), and LAG3 (r=0.348, P=4.1e-16)

• Spatial analysis considerations:

  • Analyze marker relationships within specific compartments (tumor nests vs. stroma)

  • Assess cell-to-cell proximities (e.g., distance between SLC10A3+ cells and immune cells)

  • Evaluate clustering patterns of co-expressing cells

• Visualization approaches:

  • Scatter plots with regression lines for correlation visualization

  • Heatmaps for multi-marker correlation matrices

  • Spatial maps showing co-localization patterns within tissue architecture

• Biological interpretation guidelines:

  • Strong positive correlations may indicate functional relationships or shared regulatory mechanisms

  • Consider both direct and indirect interactions in biological interpretation

  • Validate key correlations with functional studies (e.g., co-culture experiments)

How can SLC10A3 antibodies be used to investigate potential therapeutic targets in cancer immunotherapy?

Recent research has identified correlations between SLC10A3 expression and multiple immune checkpoint molecules, suggesting potential applications in cancer immunotherapy research. Investigators can use SLC10A3 antibodies to:

• Evaluate co-expression patterns of SLC10A3 with immune checkpoints like PD-1, PD-L1, and LAG3 in patient samples before and after immunotherapy

• Stratify patient cohorts based on SLC10A3 expression levels to identify subgroups that might benefit from specific immunotherapy approaches

• Develop co-targeting strategies based on SLC10A3 and immune checkpoint expression patterns

• Investigate the functional consequences of SLC10A3 inhibition or knockdown on immune cell function and cancer cell phenotypes

• Monitor changes in SLC10A3 expression during treatment as a potential biomarker of response or resistance to immunotherapy

What technological advances are improving the utility of SLC10A3 antibodies in research?

Several technological advances are enhancing the research applications of SLC10A3 antibodies:

• High-dimensional tissue analysis:

  • Multiplex immunohistochemistry techniques allow simultaneous detection of SLC10A3 with multiple immune markers in the same tissue section

  • Mass cytometry (CyTOF) and imaging mass cytometry enable analysis of dozens of markers including SLC10A3 in single cells

• Single-cell approaches:

  • Integration of antibody-based detection with single-cell RNA sequencing

  • Spatial transcriptomics for correlating SLC10A3 protein expression with gene expression profiles in tissue context

• Automated image analysis:

  • Machine learning algorithms for unbiased quantification of SLC10A3 expression patterns

  • Deep learning approaches for cell classification and spatial relationship analysis

• Functional antibody applications:

  • Development of function-blocking SLC10A3 antibodies for mechanistic studies

  • Antibody-drug conjugates targeting SLC10A3 for therapeutic exploration

• In vivo imaging:

  • Labeled SLC10A3 antibodies for non-invasive imaging of expression in preclinical models

  • Correlative studies between in vivo imaging and ex vivo tissue analysis

How should researchers interpret seemingly contradictory findings regarding SLC10A3 function across different tissue types and disease states?

When encountering contradictory findings regarding SLC10A3 function, researchers should consider:

• Tissue-specific effects:

  • SLC10A3 may have distinct functions in different tissues based on the local microenvironment

  • Expression patterns observed in brain tumors may differ from those in other cancer types or normal tissues

• Methodological differences:

  • Variations in antibody clones, detection methods, and scoring systems may contribute to apparent contradictions

  • Standardization of protocols and reporting is essential for meaningful cross-study comparisons

• Context-dependent functions:

  • SLC10A3 may exhibit different functions depending on disease stage, immune context, or molecular subtype

  • Consider the influence of other genetic alterations that may modify SLC10A3 function

• Integration of multi-omics data:

  • Combine antibody-based protein detection with transcriptomic, genomic, and epigenomic analyses

  • Conduct pathway enrichment analyses to understand biological context of SLC10A3 in different conditions

• Validation in multiple cohorts:

  • Confirm findings across independent patient cohorts and experimental models

  • Meta-analysis approaches may help resolve contradictory findings by identifying consistent patterns across studies